Author Since: July 19, 2021
Generating scientific platform and customer-specific scientific narratives


A medium size company with a novel drug in late-stage development for a neurological indication was getting behind on developing a scientific platform and a scientific narrative for the product, due to a). insufficient staffing of the medical team supporting the drug in development; b) lack of internal expertis...

Measuring the Effectiveness of Field Reimbursement Teams


A large biotech company had invested significant resources in reimbursement support, including Field Reimbursement Managers (FRMs). The organization was frustrated by the lack of quantitative metrics to evaluate and assess the effectiveness of the FRMs and asked BCA to develop an approach to address this gap.



Transitioning to Customer Driven Models


Large pharma organization desired a radical shift to customer-driven models utilizing the following criteria:
  • Reducing traditional sales representative headcount by 50%,
  • Deploying new account management resources against key influencers including payers, providers, employers, academia, ...

Segmentation of Payer Accounts/Customer


The client, a large U.S.-based pharmaceutical company had the leading product in a mature market. There were six products in category, including a new low-price entry. The key issue the organization faced was the lack of clinical differentiation among products which had resulted in ancillary product features being the primary m...

CIO Advisory Pre-Commercial Biotech US Market Launch

Challenge:  SCYNEXIS was launching Brexafemme, a pill treatment for oral treatment designed to eliminate the yeast causing infection in September 2021. Brexafemme is The first modern prescription oral treatment the market. They had not IT strategy and limited Systems and no support IT for a Commercial launch Solution:  Implem...

CIO Advisory Rare Disease Orphan Drug US Market Launch

Challenge:  Callidatas US was launching Nefecon, a capsule treatment for IgA Nephropathy (IgAN) for the US in November 2021. Nefecon is an orphan drug for rare diseases. They also needed to be preparing for Fruquintinib in 2023. They had no IT strategy nor any Systems in place to enable and support the launch. The commercialization would ...